Viking Therapeutics registers Phase 1 study of VK2735 in obese adults without comorbidities
Viking Therapeutics has registered a new Phase 1 trial testing multiple dose regimens of VK2735 in obese adults, with recruitment underway.
Viking Therapeutics posted one new trial registration this week.
- VK2735, a Phase 1 drug candidate, is listed in a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.1 The study is recruiting, with approximately 270 participants planned across two study parts, Part A and Part B.1 Primary completion is estimated for 2027-05.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.